InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (1 ops.)
Insider track record
ExecutiveDisclosed buys
1
Disclosed sells
1
T+90 hit rate
0%
T+90 mean return
-84.7%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by Loerop James, Vice-Président Exécutif du Développement Commercial. Insider active across 3 companies, notably Anika Therapeutics, Inc.. Aggregated, 15 reports have been recorded. Breakdown: 1 buy · 1 sell. Total volume traded: €148k. Activity tracked since 8 July 2021. The latest transaction was disclosed on 1 February 2025 (Retenue fiscale). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Loerop James
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations15 total
20,875 sharesCommon StockSEC:0001781549-26-000011:0
11,250 sharesCommon StockSEC:0001781549-26-000009:0
15,980 shares@ US$2.4817.1% of flowCommon StockSEC:0001781549-26-000007:0
15,980 shares@ US$2.4814.6% of flowCommon StockSEC:0001781549-26-000005:0
73,750 sharesCommon StockSEC:0001781549-26-000003:0
15,447 shares@ US$2.4816.6% of flowCommon StockSEC:0001415889-25-002938:3
7,500 sharesCommon StockSEC:0001415889-25-002938:1
11,250 sharesCommon StockSEC:0001415889-25-002938:0
14,750 sharesCommon StockSEC:0001415889-25-002938:2
73,750 sharesCommon StockSEC:0001415889-25-000622:0
11,250 sharesCommon StockSEC:0001209191-24-002838:0
14,705 shares@ US$6.797641.5% of flowCommon StockSEC:0001209191-23-047522:0
Canonical exit: 26 Nov 2023 (T+90)
4,267 shares@ US$13.890924.8% of flowCommon StockSEC:0001209191-23-008451:0
11,250 sharesCommon StockSEC:0001209191-23-006999:0
3,000 shares0Common StockSEC:0001171843-21-004833:0
15 of 15 declarations
About Loerop James
Loerop James is Executive Vice President of Business Development. He has 15 filings in total, and across the 15 sampled filings the recorded volumes relate to Aclaris Therapeutics, Inc., with EUR 92336 of buys and EUR 55241 of sells, over the period from 2021-07-12 to 2026-02-05. The most common transaction nature is option exercise.
